£520.00

The 2023-2028 Outlook for Anxiety Disorders and Depression Treatments in the United States

Subjects

Price data last checked 17 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£520 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 74 days · 74 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 74 days • 1 price levels

Days at Price

Price Analysis

Most common price: £520 (74 days, 100.0%)

Price range: £520 - £520

Price levels: 1 different prices over 74 days

Description

This study covers the latent demand outlook for anxiety disorders and depression treatments across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for anxiety disorders and depression treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anxiety disorders and depression treatments as including all commonly understood products falling within this broad category, such as selective serotonin and serotonin-norepinephrine reuptake inhibitors; atypical antipsychotics; monoamine oxidase inhibitors, tetracyclic antidepressants, and anticonvulsants; and beta-blockers, benzodiazepines, and tricyclic antidepressants, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Merck & Company, Pfizer Inc. (US), and Sanofi-Aventis. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BLQYK3T1
Category: Books > Subjects
Domain: Amazon UK
Release Date: 26 October 2022
Listed Since: 09 November 2022

The 2023-2028 Outlook for Anxiety Disorders and Depression Treatments in the United States

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Anxiety Disorders and Depression in the United States

The 2023-2028 Outlook for Anxiety Disorder Treatments in the United States

The 2023-2028 Outlook for Anxiety Disorder Therapeutics in the United States

The 2023-2028 Outlook for Antidepressants for Anxiety Disorders in the United States

The 2026-2031 World Outlook for Antidepressants for Anxiety Disorders

The 2026-2031 World Outlook for Antidepressant and Anti-Anxiety Drugs

The 2023-2028 Outlook for Antidepressants for Major Depressive Disorders in the United States

The 2016-2021 Outlook for Antidepressant Pharmaceuticals in Japan

The 2023-2028 Outlook for Stress Management Treatments in the United States

The 2023-2028 Outlook for Stress Management Treatments in India

The 2026-2031 World Outlook for Antidepressant Drugs

The 2026-2031 World Outlook for Antidepressants

The 2023-2028 Outlook for Antidepressants for Major Depressive Disorders in China

The 2021-2026 World Outlook for Antidepressants

The 2026-2031 World Outlook for Antidepressant Pharmaceuticals

The 2021-2026 World Outlook for Major Depressive Disorder (MDD) Therapeutics

The 2026-2031 World Outlook for Antidepressants for Major Depressive Disorders

The 2023-2028 Outlook for Personal Therapy Products in the United States

Anxiety Disorders: From Childhood to Adulthood

The 2023-2028 World Outlook for Stress Management Treatments

Anxiety and Depression in Primary Care: International Perspectives (WONCA Family Medicine)

Treatments for Anxiety: Fact versus Fiction

The 2023-2028 Outlook for Antidepressants for Major Depressive Disorders for US Zip Codes

The Self in Anxiety, Stress and Depression